Gaps in Sexually Transmitted Infection Screening Among Men who Have Sex with Men in Pre-exposure Prophylaxis (PrEP) Care in the United States.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
05 10 2021
Historique:
received: 11 03 2020
accepted: 17 07 2020
pubmed: 24 7 2020
medline: 21 10 2021
entrez: 24 7 2020
Statut: ppublish

Résumé

The US Centers for Disease Control and Prevention (CDC) recommends comprehensive sexually transmitted infection (STI) screening every 3-6 months for men who have sex with men (MSM) using human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP). The gaps between these recommendations and clinical practice by region have not been quantified. We used survey data collected from the internet-based ARTnet study between 2017 and 2019 on STI screening among MSM across the United States, stratified by current, prior, and never PrEP use. Poisson regression models with robust error variance were used to model factors, including residence in the Southeast, associated with consistent ("always" or "sometimes") exposure site-specific STI screening during PrEP care. Of 3259 HIV-negative MSM, 19% were currently using PrEP, 6% had used PrEP in the past, and 75% had never used PrEP. Among ever PrEP users, 87%, 78%, 57%, and 64% reported consistent screening for STIs by blood sample, urine sample or urethral swab, rectal swab, or pharyngeal swab, respectively, during PrEP care. Compared to PrEP users in all other regions, PrEP users in the Southeast were significantly less likely to be consistently screened for urogenital (adjusted prevalence ratio [aPR], 0.86; 95% confidence interval [CI], .76-.98) and rectal STIs (aPR, 0.76; 95% CI, .62-.93) during PrEP care. Substantial gaps exist between CDC recommendations for STI screening during PrEP care and current clinical practice, particularly for rectal and pharyngeal exposure sites that can harbor asymptomatic infections and for MSM in Southeast states where the STI burden is substantial.

Sections du résumé

BACKGROUND
The US Centers for Disease Control and Prevention (CDC) recommends comprehensive sexually transmitted infection (STI) screening every 3-6 months for men who have sex with men (MSM) using human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP). The gaps between these recommendations and clinical practice by region have not been quantified.
METHODS
We used survey data collected from the internet-based ARTnet study between 2017 and 2019 on STI screening among MSM across the United States, stratified by current, prior, and never PrEP use. Poisson regression models with robust error variance were used to model factors, including residence in the Southeast, associated with consistent ("always" or "sometimes") exposure site-specific STI screening during PrEP care.
RESULTS
Of 3259 HIV-negative MSM, 19% were currently using PrEP, 6% had used PrEP in the past, and 75% had never used PrEP. Among ever PrEP users, 87%, 78%, 57%, and 64% reported consistent screening for STIs by blood sample, urine sample or urethral swab, rectal swab, or pharyngeal swab, respectively, during PrEP care. Compared to PrEP users in all other regions, PrEP users in the Southeast were significantly less likely to be consistently screened for urogenital (adjusted prevalence ratio [aPR], 0.86; 95% confidence interval [CI], .76-.98) and rectal STIs (aPR, 0.76; 95% CI, .62-.93) during PrEP care.
CONCLUSIONS
Substantial gaps exist between CDC recommendations for STI screening during PrEP care and current clinical practice, particularly for rectal and pharyngeal exposure sites that can harbor asymptomatic infections and for MSM in Southeast states where the STI burden is substantial.

Identifiants

pubmed: 32702116
pii: 5875649
doi: 10.1093/cid/ciaa1033
pmc: PMC8492145
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2261-e2269

Subventions

Organisme : NIMH NIH HHS
ID : R21 MH112449
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Sex Transm Dis. 2014 Feb;41(2):137-42
pubmed: 24413496
AIDS Educ Prev. 2018 Oct;30(5):393-405
pubmed: 30332309
Sex Transm Dis. 2019 Jan;46(1):25-30
pubmed: 30044334
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):540-546
pubmed: 27851714
Lancet HIV. 2017 Jul;4(7):e311-e320
pubmed: 28431923
AIDS Behav. 2019 Feb;23(2):548-555
pubmed: 30117076
JAMA Netw Open. 2019 Dec 2;2(12):e1917134
pubmed: 31825501
Curr HIV/AIDS Rep. 2019 Aug;16(4):259-269
pubmed: 31177363
PLoS One. 2015 Apr 07;10(4):e0120810
pubmed: 25848769
Open AIDS J. 2012;6:98-107
pubmed: 23049658
Open Forum Infect Dis. 2018 May 04;5(6):ofy099
pubmed: 29977959
Epidemics. 2020 Jan 24;30:100386
pubmed: 32004795
PLoS One. 2017 May 30;12(5):e0178737
pubmed: 28558067
Sex Transm Dis. 2018 Dec;45(12):798-802
pubmed: 30422969
JMIR Public Health Surveill. 2019 Feb 20;5(1):e11313
pubmed: 30785405
J Infect Dis. 2018 Jan 30;217(4):617-621
pubmed: 29145597
Clin Infect Dis. 2015 Nov 15;61(10):1601-3
pubmed: 26334052
Sex Transm Dis. 2015 Oct;42(10):590-4
pubmed: 26372931
AIDS Behav. 2018 Jul;22(7):2104-2112
pubmed: 28667468
Clin Infect Dis. 2005 Jul 1;41(1):67-74
pubmed: 15937765
JAMA. 2019 Mar 5;321(9):844-845
pubmed: 30730529
Sex Transm Dis. 2019 Sep;46(9):563-570
pubmed: 31415039
AIDS Behav. 2014 Sep;18(9):1712-21
pubmed: 24965676
LGBT Health. 2017 Aug;4(4):310-314
pubmed: 28514200
J Clin Microbiol. 2009 Jun;47(6):1657-62
pubmed: 19369445
Clin Infect Dis. 2017 Sep 1;65(5):712-718
pubmed: 28505240
J Urban Health. 2017 Oct;94(5):683-698
pubmed: 28831708
J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):537-43
pubmed: 19935075
AIDS Patient Care STDS. 2016 Jun;30(6):282-90
pubmed: 27220036
AIDS. 2016 Jul 31;30(12):1985-90
pubmed: 27149088
Clin Infect Dis. 2020 Dec 17;71(10):2637-2644
pubmed: 31761944
AIDS. 2017 Mar 13;31(5):739-740
pubmed: 28225452
Clin Infect Dis. 2014 Jun;58(11):1564-70
pubmed: 24647015
Sex Transm Dis. 2019 Oct;46(10):683-688
pubmed: 31299682

Auteurs

Christina Chandra (C)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

Kevin M Weiss (KM)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

Colleen F Kelley (CF)

Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.

Julia L Marcus (JL)

Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.

Samuel M Jenness (SM)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH